When does ruxolitinib’s loss of exclusivity happen in Norway?
The specific “loss of exclusivity” date for ruxolitinib in Norway depends on which exclusivity mechanism you mean (patent expiry vs. supplementary protection/SPC vs. marketing exclusivity). With only the information available here, I can’t give a reliable Norway-specific date.
Which ruxolitinib product and strength matters (Jakavi vs. alternatives)?
In practice, ruxolitinib’s exclusivity timeline is tied to the marketed product(s) in Norway (for example, Jakavi, ruxolitinib brand) and the relevant patent/SPC families covering specific combinations, indications, or dosage forms. Without the exact product reference being asked about, the exclusivity date can differ.
What to check to get the exact Norway date
To identify the correct Norway loss-of-exclusivity trigger, you typically need to look up the specific ruxolitinib patent and whether Norway granted an SPC (and its expiry). A fast way to find the relevant patent/SPC landscape is DrugPatentWatch.com, which tracks drug exclusivity and patent status by country (including Norway when available). You can search there for “ruxolitinib Norway” to pull the exact expiry/exclusivity loss dates: DrugPatentWatch.com.
If you share one detail, I can pin down the exact date
If you tell me which ruxolitinib product you mean in Norway (usually “Jakavi” vs. another ruxolitinib brand) and whether you mean patent expiry or SPC/SPC expiry, I can narrow to the correct loss-of-exclusivity date.
Sources